{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:08:10Z","timestamp":1784308090918,"version":"3.55.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","award":["NIHR 203308"],"award-info":[{"award-number":["NIHR 203308"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012295","name":"Newcastle Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic treatments for psoriasis could increase the risk of serious infection due to their inhibitory effect on the immune system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate and compare the serious infection risk associated with systemic treatments for psoriasis<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with psoriasis who received at least one of the systemic treatments and had 6-month follow-up data recorded in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) database were included in the analysis. Patients were followed from the time of drug initiation to drug discontinuation, death or last available follow-up date. Infections that occurred during or up to 90\u2005days after treatment discontinuation resulting in hospitalization, the administration of intravenous antimicrobials or death were considered serious. Inverse probability of treatment weighting was used to balance baseline covariates. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated using a piece-wise Cox proportional hazards model. A recurrent event analysis was also performed using the\u00a0Prentice\u2013Williams\u2013Peterson model. Missing data were handled using multiple imputation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 46 770 treatment episodes from 18 976 patients were analysed. Patients were predominantly men (n = 10 893; 57.4%) and had a mean (SD) age of 45.64 (13.67) years and a mean (SD) BMI of 31.60 (7.28) kg m\u20132. The incidence rate of serious infections was 27.67 events per 1000 person-years (95% CI 26.72\u201328.65) and the rate of recurrent serious infection in those with prior infection was 78.70 events per 1000 person-years (95% CI 75.17\u201382.36). The piecewise Cox proportional hazards model showed an increased risk of serious infection with apremilast (HR 1.53, 95% CI 1.27\u20131.80) and secukinumab (HR 1.34, 95% CI 1.18\u20131.50) compared with adalimumab. However, these findings were not consistent across sensitivity analyses. The recurrent event analysis showed a lower risk with risankizumab than with brodalumab (HR 0.74, 95% CI 0.55\u20130.99), etanercept (HR 0.75, 95% CI 0.60\u20130.94) and standard treatments (HR 0.80, 95% CI 0.65\u20130.98). Serious infection-associated deaths were rare (incidence rate 1.81 per 1000 person-years, 95% CI 1.57\u20132.07).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite isolated signals in the time-to-first event analysis, the more robust recurrent event analysis showed that risankizumab was associated with a lower risk of serious infections, while no significant differences were observed among the other systemic treatments for psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag174","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:26:53Z","timestamp":1777724813000},"page":"261-269","source":"Crossref","is-referenced-by-count":1,"title":["Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of\u00a0Dermatologists Biologics and Immunomodulators Register (BADBIR)"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3149-5750","authenticated-orcid":false,"given":"Heber Rew Bright","family":"Bright","sequence":"first","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"Catherine H","family":"Smith","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, King\u2019s College London and Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-0699","authenticated-orcid":false,"given":"Philip","family":"Laws","sequence":"additional","affiliation":[{"name":"University of Leeds, Chapel Allerton Hospital , Leeds ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6484-825X","authenticated-orcid":false,"given":"Nick J","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Institute of Translational and Clinical Medicine, Newcastle University and NIHR Biomedical Research Centre and Department of Dermatology, Royal\u00a0Victoria\u00a0Infirmary, Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8916-9093","authenticated-orcid":false,"given":"Duc Binh","family":"Phan","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2391-5575","authenticated-orcid":false,"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences, The University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester , Manchester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026071712535933700_ljag174-B1","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00018-020-03726-1","article-title":"Immune responses and therapeutic options in psoriasis","volume":"78","author":"Afonina","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"2026071712535933700_ljag174-B2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jaad.2017.07.047","article-title":"Serious infections among a large cohort of subjects with systemically treated psoriasis","volume":"77","author":"Dobry","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026071712535933700_ljag174-B3","doi-asserted-by":"crossref","first-page":"e15006","DOI":"10.1111\/ijcp.15006","article-title":"Association between different systemic therapies and the risk of tuberculosis in psoriasis patients: a population-based study","volume":"75","author":"Ting","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2026071712535933700_ljag174-B4","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2014.4956","article-title":"Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study","volume":"151","author":"Shalom","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026071712535933700_ljag174-B5","doi-asserted-by":"crossref","first-page":"2442603","DOI":"10.1155\/2022\/2442603","article-title":"Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials","volume":"2022","author":"Feng","year":"2022","journal-title":"Int J Clin Pract"},{"key":"2026071712535933700_ljag174-B6","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231206225","article-title":"Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Chiu","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"2026071712535933700_ljag174-B7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s13555-025-01578-w","article-title":"Serious infection risk with systemic treatments for psoriasis: a systematic review and network meta-analysis combining randomised and non-randomised evidence","volume":"16","author":"Bright","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026071712535933700_ljag174-B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.024","article-title":"Infection risk among psoriasis biologic-new users: a cohort study on the French National Health Data System","author":"Le","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"2026071712535933700_ljag174-B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2026.03.004","article-title":"Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry","author":"Olivares-Guerrero","year":"2026","journal-title":"J Invest Dermatol"},{"key":"2026071712535933700_ljag174-B10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/bjd\/ljag032","article-title":"Serious infection risk in people treated with infliximab for severe psoriasis","volume":"194","author":"Bright","year":"2026","journal-title":"Br J Dermatol"},{"key":"2026071712535933700_ljag174-B11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","article-title":"Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis","volume":"155","author":"Dommasch","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026071712535933700_ljag174-B12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026071712535933700_ljag174-B13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","article-title":"Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Yiu","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2026071712535933700_ljag174-B14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/nep.13742","article-title":"Evidence-based medicine \u2013 when observational studies are better than randomized controlled trials","volume":"25","author":"Bosdriesz","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"2026071712535933700_ljag174-B15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2133.2012.10835.x","article-title":"The British Association of Dermatologists\u2019 Biologic Interventions Register (BADBIR): design, methodology and objectives","volume":"166","author":"Burden","year":"2012","journal-title":"Br J Dermatol"},{"key":"2026071712535933700_ljag174-B16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjd.17421","article-title":"Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy","volume":"180","author":"Yiu","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026071712535933700_ljag174-B17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2025.0144","article-title":"Systemic therapies for psoriatic disease and serious infections in older adults","volume":"161","author":"Drucker","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026071712535933700_ljag174-B18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","article-title":"Association between biologics use and risk of serious infection in patients with psoriasis","volume":"157","author":"Penso","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026071712535933700_ljag174-B19","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/acr.24630","article-title":"Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis","volume":"74","author":"Jin","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026071712535933700_ljag174-B20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","article-title":"Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026071712535933700_ljag174-B21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/rheumatology\/keac358","article-title":"Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries","volume":"62","author":"Glintborg","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026071712535933700_ljag174-B22","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1473-3099(20)30978-6","article-title":"Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study","volume":"21","author":"Drozd","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026071712535933700_ljag174-B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12879-021-05811-7","article-title":"Incidence, healthcare-seeking behaviours, antibiotic use and natural history of common infection syndromes in England: results from the Bug Watch community cohort study","volume":"21","author":"Smith","year":"2021","journal-title":"BMC Infect Dis"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag174\/68209511\/ljag174.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/2\/261\/68209511\/ljag174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/195\/2\/261\/68209511\/ljag174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:54:04Z","timestamp":1784307244000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/195\/2\/261\/8667157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,7,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag174","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,5]]}}}